Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010–2016)

• Published in: Virus genes Vol. 54; no. 1; pp. 41 - 47
• Main Authors: Zhang, Hong-yu, Liu, Long-gen, Ye, Chun-yan, Chen, Chun-hua, Hang, Shuang-xiong, Zhu, Zhen, Shen, Hong-yu, Huang, Ze-yu, Chen, Wen-yi, Xue, Yuan
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2018; Springer Nature B.V
• Subjects: Antiviral Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Drug resistance; Drug Resistance, Viral; Evolution, Molecular; Gene Frequency; Genome, Viral; Genomes; Genotypes; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B virus - isolation & purification; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - virology; Humans; Medical Microbiology; Mutation; Patients; Plant Sciences; Point mutation; Treatment Failure; Virology; Resistance; Long-term analysis; Nucleos(t)ide analogues; Hepatitis B virus; Mutation
• ISSN: 0920-8569; 1572-994X
• DOI: 10.1007/s11262-017-1518-z

The objective of this study was to analyze the prevalence of drug-resistant HBV mutants in patients with treatment failure during the past seven years (2010–2016). 4055 HBV-infected patients who underwent HBV polymerase gene mutation test from 2010 to 2016 were enrolled. The nucleos(t)ide analogues (NAs) resistance mutation positions, including rtL180, rtA181, rtT184, rtS202, rtM204, rtI233, rtN236, rtI169, rtV173, and rtM250 were analyzed. Genotypic resistance mutations were detected in 30.8% (1248/4055) of the patients with treatment failure. Rates of drug-resistant mutations associated with LAM, ADV, ETV, and multidrug were 27.23% (1104/4055), 9.67% (392/4055), 3.69% (150/4055), and 0.79% (32/4055). Among the primary NA-resistant mutations, rtM204I (13.44%, 545/4055) occurred more frequently, followed by rtM204V, rtN236T, rtA181T, and rtA181V. For single-base mutations, rtL180M and rtA181V increased gradually during the past seven years, while rtM204I/V and rtN236T decreased after 2015. The development of drug-resistant mutations positively correlated with the consumption of ETV ( r  = 0.964, P  = 0.002), and weakly correlated with that of LAM ( r  = 0.679, P  = 0.109) and ADV ( r  = 0.429, P  = 0.354). Moreover, single-base mutation rtA181V and multi-base mutations (rtL180M + M204I and rtL180M + M204V + M204I) were more common in HBV genotype C than those in genotype B (1.94% vs. 0.66%, 1.84% vs. 0.16%, 1.02% vs. 0.16%, respectively). NA-related mutations in HBV RT region increased in the past seven years, especially for LAM. Frequencies of rtL180M and rtA181T/V increased gradually in the past seven years, to which we should pay more attention.